Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.84
UNSPSC Code:
12161503
Product Name
MILLIPLEX® Human IL-18 Singleplex,
description
Human IL-18 Singleplex Kit
species reactivity
human
packaging
pkg of 1 ea
manufacturer/tradename
Milliplex®
technique(s)
multiplexing: suitable
input
cell culture supernatant(s)
plasma
serum
detection method
fluorometric (Luminex® xMAP® technology)
shipped in
wet ice
storage temp.
2-8°C
General description
Interleukin-18 (IL-18) is a pro-inflammatory cytokine that plays a crucial role in the immune response by promoting the activation and proliferation of T cells and natural killer (NK) cells. It is primarily produced by macrophages and dendritic cells and is involved in various physiological processes, including inflammation, infection, and autoimmune diseases. Elevated levels of IL-18 have been associated with several conditions, such as cardiovascular diseases, cancer, and chronic inflammatory disorders, making it an important biomarker for research and therapeutic targets.
Application
MILLIPLEX® Qualified assays undergo rigourous assay development, verification, and Quality Control testing to achieve optimal performance. Analyze IL-18 in human serum, plasma, and cell culture supernatants.
Analytes included: IL-18
Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Analytes included: IL-18
Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Features and Benefits
- Facilitates Biomarker Discovery: Useful in studying diseases where IL-18 plays a role, such as autoimmune disorders, infections, and cancer.
- User-Friendly: The straightforward protocol makes it accessible even for labs with limited experience in cytokine assays.
- Multiplexing Flexibility: The IL-18 kit can be combined with other MILLIPLEX® kits, allowing for the simultaneous measurement of multiple cytokines and biomarkers in a single sample.
Legal Information
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Disclaimer
For research use only. Not for use in diagnostic procedures.
Label License/Sticker for Assay Product:
By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
Label License/Sticker for Assay Product:
By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
signalword
Danger
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2
target_organs
Respiratory Tract
Storage Class
10 - Combustible liquids
wgk
WGK 3
Regulatory Information
新产品
This item has
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Gyoung Nyoun Kim et al.
PLoS pathogens, 17(12), e1010092-e1010092 (2021-12-17)
The development of safe and effective vaccines to prevent SARS-CoV-2 infections remains an urgent priority worldwide. We have used a recombinant vesicular stomatitis virus (rVSV)-based prime-boost immunization strategy to develop an effective COVID-19 vaccine candidate. We have constructed VSV genomes